What Is 21 CFR 11

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 21 CFR Part 11 is a U.S. FDA regulation from 1997 that establishes requirements for electronic records and signatures in regulated industries. It ensures the authenticity, integrity, and confidentiality of digital data used in clinical trials, manufacturing, and quality control.

Key Facts

21 CFR Part 11 was issued by the FDA in March 1997
Applies to pharmaceutical, biotech, and medical device manufacturers
Requires audit trails for all electronic record changes
Mandates two-factor authentication for electronic signatures
Allows the FDA to inspect electronic systems during audits

Overview

21 CFR Part 11 is a regulation established by the U.S. Food and Drug Administration (FDA) to govern the use of electronic records and electronic signatures in regulated industries. It ensures that digital data is trustworthy, equivalent in legal standing to paper records, and resistant to tampering.

The regulation applies primarily to industries under FDA oversight, including pharmaceuticals, biotechnology, and medical devices. Compliance is essential for companies submitting data to the FDA for product approvals, inspections, or ongoing compliance monitoring.

Effective date: The final rule for 21 CFR Part 11 went into effect on August 20, 1997, after a proposed rule in 1992 and extended comment periods.
Scope: It covers electronic records used in clinical investigations, manufacturing, labeling, and quality control processes subject to FDA regulations.
Electronic signatures: Must be linked to a specific individual and include date, time, and user identity to ensure accountability.
Audit trails: Systems must maintain secure, computer-generated, time-stamped audit trails that record all changes to electronic records.
Validation: Companies must validate that electronic systems perform as intended throughout their lifecycle, including updates and patches.

How It Works

21 CFR Part 11 sets technical and procedural standards to ensure electronic records are secure, traceable, and legally defensible. It defines specific controls for access, modification, and authentication to prevent unauthorized use or data manipulation.

Electronic Records: Digital data must be accurate, complete, and protected from unauthorized access. This includes databases, spreadsheets, and instrument outputs used in regulated processes.
Electronic Signatures: Must include at least two identification components, such as a username and password, and a biometric or digital certificate, to verify identity.
System Validation: Software and systems must undergo formal validation protocols to prove they consistently produce reliable results under defined conditions.
Access Controls: Systems must enforce role-based permissions so only authorized personnel can create, modify, or approve electronic records.
Record Retention: Electronic records must be stored in a way that preserves readability and integrity for the required retention period, typically 2–25 years depending on the record type.
Security Measures: Includes encryption, audit trails, and backup systems to prevent data loss, tampering, or unauthorized access.

Comparison at a Glance

Below is a comparison of 21 CFR Part 11 with related standards and paper-based systems:

Feature	21 CFR Part 11	Traditional Paper Records	GDPR
Data Integrity	Requires audit trails and system validation	Relies on physical storage and manual tracking	Focuses on lawful processing and consent
Signature Validity	Requires two-factor authentication	Uses handwritten signatures	Accepts electronic signatures under eIDAS
Scope	Applies to FDA-regulated industries	Universal but less secure	Applies to all EU personal data
Enforcement	Enforced by FDA inspections	Subject to internal audits	Enforced by EU data protection authorities
Record Retention	2–25 years, depending on record type	Same duration, but physical degradation possible	Varies by data type and jurisdiction

While 21 CFR Part 11 focuses on data integrity in regulated life sciences, GDPR emphasizes privacy and individual rights. Paper records lack the auditability and security of validated electronic systems, making them less compliant with modern regulatory expectations.

Why It Matters

21 CFR Part 11 is critical for ensuring trust in digital systems used in drug development, manufacturing, and quality assurance. Without it, the FDA could not accept electronic submissions, slowing innovation and increasing compliance costs.

Regulatory Compliance: Non-compliance can result in formal warnings, import detentions, or product recalls during FDA inspections.
Global Acceptance: Many countries reference 21 CFR Part 11 in their own regulations, making it a global benchmark for electronic records.
Efficiency Gains: Validated electronic systems reduce paperwork, storage costs, and retrieval time compared to manual processes.
Data Integrity: Audit trails and access controls prevent data falsification and ensure traceability during investigations.
Supports Innovation: Enables use of electronic lab notebooks, LIMS, and automated manufacturing systems in FDA-regulated environments.
Legal Defensibility: Electronic signatures under Part 11 are legally binding and admissible in court or regulatory hearings.

As digital transformation accelerates in healthcare and life sciences, adherence to 21 CFR Part 11 remains essential for regulatory approval, data credibility, and patient safety.